Global Perspective in Advanced, Recurrent Cervical Cancer: Resources, Opportunities and Access to Care Industry Supported Symposium

This educational session explores the evolving global landscape of advanced and recurrent cervical cancer, with a focus on disparities in access to care and treatment innovations. Participants will review pivotal clinical trial data shaping current treatment paradigms, including the role of antibody-drug conjugates (ADCs) as a novel therapeutic option. Emphasis will be placed on how to compare and contrast global differences in treatment landscape and novel therapy implementation. Pearls for successful implementation of TV patient education, disease prevalence, and prevention strategies, with a spotlight on African regional statistics and global efforts to eliminate cervical cancer. The session will also highlight the World Health Organization’s approach to improving overall survival and discuss opportunities for healthcare professionals to contribute to global cervical cancer elimination initiatives.

This educational activity is supported by an independent medical education grant from Genmab

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will be able to:

• Review the current landscape for the treatment of recurrent cervix cancer based on pivotal clinical trial data and current insights.
• Understand the role of ADC in cervix cancer, and how to educate patients on this novel treatment option.
• Review and understand prevalence of disease, prevention and available resources.